Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Immunotherapy for Advanced Liver Cancer
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2